Objectives: To assess predictors of residual shunts after percutaneous PFOclosure with Amplatzer PFO occluder. 
Introduction
In patients with stroke of unknown etiology (cryptogenic stroke) and a patent foramen ovale (PFO), percutaneous closure has been advocated as an alternative strategy to lifelong antithrombotic therapy, particularly in the presence of associated atrial septal aneurysms and in young individuals.
While several types of occluders for PFO device closure are available in the market, the Amplatzer PFO occluder (AGA Medical Corporation, Golden Valley, Minnesota) currently is still the most widely used. One limitation of any percutaneous device closure is the possible persistence of a residual shunt, which may occur in up to 29% [1] . An association between residual shunts and recurrent ischemic events has been demonstrated [2, 3, 4, 5] but little is known about predictors of residual shunts after percutaneous PFO-closure.
Aim of the study
We sought to identify predictors of a residual shunt six months after percutaneous PFO closure with the Amplatzer PFO occluder. aneurysm was defined as a maximum deflection of the atrial septum of at least 15mm on M-Mode recording perpetual to the atrial septum [6] . The devices used were 25mm-and 35mm-Amplatzer PFO occluders at the discretion of the operator. The procedure was performed under local anaesthesia and fluoroscopic control, without periprocedural echocardiography. All patients were loaded with Aspirin prior to the procedure and oral double antiplatelet therapy with Aspirin and Clopidogrel was maintained for 3 months, followed by Aspirin only for an additional 3 months.
Methods
Patients with a history of previous stroke or TIA were kept on treatment with low dose Aspirin thereafter, irrespective of the presence of a residual shunt. A chest radiograph was performed routinely the day after the procedure. All patients had an outpatient follow up visit after six months, including a comprehensive transthoracic and transesophageal echocardiography with saline contrast injection.
Outcomes:
The main outcome measure was the presence of a residual interatrial shunt at six months follow-up, detected by TTE or TEE after intravenous injection of agitated saline contrast. Secondary outcome measures were recurrence of ischemic events, periprocedural complications and complications during follow-up.
Statistical analysis:
Continuous variables were expressed as means (SD), and differences among the groups of patients were tested with Student's ttest. Categorical data were presented as actual numbers and percentages, and a Chi-squared test was used to test for differences among the groups. Statistical significance was assumed with a two-sided p value < 0.05. The index event for closure of the PFO was a transient ischemic attack in 23%, an ischemic stroke in 69%, paradoxical peripheral embolism in 4% and a diving accident in 4% of patients. Thirty four percent of patients had recurrent ischemic events prior to the intervention. Thirty-nine percent of patients had an isolated PFO, whereas in 61% of patients a concomitant atrial septal aneurysm was present. There was no difference between patients with and without recurrent embolic events regarding the presence of an atrial septal aneurysm (57% and 63% respectively, p-value = 0.58).
Results

Patients
To choose the most appropriate device size, transthoracic and transesophageal echocardiograms were carefully reviewed before every procedure. None of the patients included in this series had a multifenestrated ASA or multiple defects within the interatrial septum. The decision, whether to 
Discussion
The rate of residual interatrial shunts after PFO closure with Amplatzer devices has been investigated in several studies Comparable larger series with similar follow up modalities, described rates of residual shunts at 6 months follow up of 8-19%. [2, 3, 5, 10, 14, 17] .
In our patient group, we found a high rate of 19% residual shunts at 6 months.
This might partly be explained by the high percentage of concomitant atrial septal aneurysms in our series, reflecting the restrictive referral policy at our institution. Therefore there may have been a bias towards more residual shunts as mainly patients with large atrial septal aneurysms were referred for PFO closure.
Only few series investigated predictors of residual shunts at follow up [3, 5, 17] .
The higher rate of residual shunts in the presence of an atrial septal aneurysm could be demonstrated only in some series [5, 17] . Zajarias et al [17] described a residual shunt at 6 months follow up after percutaneous PFO closure with Amplatzer devices in 7/7 patients in the presence of an atrial septal aneurysm. Wahl et al [5] clearly demonstrated an association of a residual shunt with larger devices. This finding could not be demonstrated in the series of Zajarias [17] . In our series a 35mm occluder was used almost exclusively in patients with atrial septal aneurysms and thus, the size of the device could not be demonstrated to be an independent predictor of residual shunts.
Several factors may play a role for the fact, that residual shunts were more prevalent in patients with an atrial septal aneurysm and especially in those in whom a 35mm occluder was used. First, even the 35mm occluder may be too small to fully cover a large atrial septal aneurysm as is shown in figure 1. Second, in patients in whom a 35mm occluder is needed, the larger device may unfavourably alter the atrial septal geometry and therefore prevent proper alignment of the occluder to the atrial septum (see figure 2). Third the larger surface of the 35mm device might delay endothelialization [14] . The latter hypothesis would be supported by the finding of disappearance of a residual shunt in some patients with large devices after one year follow up.
To overcome the problem of frequent residual shunts in patients with large atrial septal aneurysms the use of other devices, for example Amplatzer ASD occluder, or the use of alternative implantation techniques, for example through a prior transseptal puncture, might be considered. Compared to the Amplatzer PFO occluder with its narrow waist, the Amplatzer ASD occluder is a self-centering device, which may proof beneficial in patients with a large PFO/ASA.
Study limitations
The main limitation of our study is the small size of our patient group and therefore the small number of patients with residual shunts. To what extent the rate of residual shunts decreases after longer follow up has not been investigated routinely.
Due to the short follow up period we could not determine, whether these mainly small residual shunts translate into a higher rate of recurrent ischemic events.
Conclusion
The presence of atrial septal aneurysms in patients undergoing percutaneous PFO closure with an Amplatzer PFO occluder significantly increases the rate of residual shunts at six months follow-up, even if 35mm devices are used.
